Localized and locally advanced bladder cancer.

Area of Science:

• Uro-oncology
• Medical oncology
• Surgical oncology

Background:

• Bladder cancer is a heterogeneous disease with varying invasive potential and treatment responses.
• Surgical advances have improved outcomes for muscle-invasive bladder cancer, but disease natural history remains unchanged.
• Chemotherapy for metastatic disease has spurred trials in early-stage, high-risk bladder cancer.

Purpose of the Study:

• To evaluate the role and survival impact of neoadjuvant chemotherapy in bladder cancer.
• To assess the efficacy of adjuvant chemotherapy in bladder cancer treatment.
• To explore bladder preservation strategies and novel therapeutic modalities.

Main Methods:

• Review of nonrandomized and randomized trials on neoadjuvant and adjuvant chemotherapy for bladder cancer.
• Analysis of data regarding perioperative outcomes and quality of life.
• Examination of emerging molecular-targeted therapies and monoclonal antibodies.

Main Results:

• Evidence for neoadjuvant chemotherapy's survival benefit in bladder cancer is inconclusive.
• Preliminary data suggest neoadjuvant chemotherapy may enable bladder preservation in select patients.
• Insufficient evidence exists to support routine adjuvant chemotherapy due to trial limitations.

Conclusions:

• The definitive role of neoadjuvant chemotherapy in bladder cancer survival requires further investigation.
• Bladder preservation may be achievable with combined neoadjuvant therapy in selected cases.
• Large-scale, multicenter trials are crucial to establish evidence-based guidelines for chemotherapy in bladder cancer.